Fig. 3: Overview of currently-approved CE-IVD products with manufacturer, task and indication (last checked on 09/2023). | Oncogene

Fig. 3: Overview of currently-approved CE-IVD products with manufacturer, task and indication (last checked on 09/2023).

From: Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption

Fig. 3

It is notable that the majority of approved applications are for tumour identification and biomarker quantification in prostate and breast cancer. In addition to the high rates of prevalence of these cancers, the tasks of tumour identification and biomarker quantification are time-consuming and difficult, and AI can improve efficiency and consistency of these in the clinic.

Back to article page